Join JT and Edson, two St. Mary's parents and scientists at AI Proteins, for a tour of the AI Proteins lab for up to four people! 

"AI Proteins is on a mission to re-imagine protein-based medicines with ideal therapeutic characteristics. Since our founding in late 2021, our team of experienced protein engineers and drug developers has built a proprietary platform that leverages synthetic biology, robotics and automation, and artificial intelligence. This enables the company to rapidly design, build, and develop highly specific, durable, and inexpensive miniprotein medicines from scratch, with the potential for a variety of administration options.

Our de novo design capabilities give us complete structural control, allowing us to create patentable miniproteins that combine the most desirable characteristics of small molecules and biologics and possess nearly unlimited therapeutic potential. We have identified novel candidates against a multitude of high value therapeutic targets, and we are currently advancing our own pipeline in oncology while exploring partnerships in inflammation, metabolic diseases and other therapeutic areas to realize the full value of our innovations."